These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12962932)

  • 21. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.
    Plotti F; Montera R; Aloisi A; Scaletta G; Capriglione S; Luvero D; De Cicco Nardone C; Basile S; Benedetti Panici P; Angioli R
    Eur J Surg Oncol; 2016 Mar; 42(3):383-90. PubMed ID: 26725211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.
    Engelen MJ; Kos HE; Willemse PH; Aalders JG; de Vries EG; Schaapveld M; Otter R; van der Zee AG
    Cancer; 2006 Feb; 106(3):589-98. PubMed ID: 16369985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Time-Varying Effect of Prognostic Factors on Survival in Ovarian Cancer.
    Chang C; Chiang AJ; Wang HC; Chen WA; Chen J
    Ann Surg Oncol; 2015 Nov; 22(12):3976-80. PubMed ID: 25777089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
    Yang ZJ; Wei RJ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of interval debulking in advanced ovarian cancer patients.
    Suprasert P; Tiyanon J; Kietpeerakool C
    Asian Pac J Cancer Prev; 2008; 9(3):519-24. PubMed ID: 18990031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stage IV ovarian cancer: impact of surgical debulking.
    Curtin JP; Malik R; Venkatraman ES; Barakat RR; Hoskins WJ
    Gynecol Oncol; 1997 Jan; 64(1):9-12. PubMed ID: 8995540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
    Drews F; Bertelli G; Lutchman-Singh K
    Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.
    Risum S; Loft A; Høgdall C; Berthelsen AK; Høgdall E; Lundvall L; Nedergaard L; Engelholm SA
    Acta Oncol; 2011 Apr; 50(3):415-9. PubMed ID: 20698810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
    Wu M; Shen K; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (≤40 years old) with borderline ovarian tumors.
    Fang C; Zhao L; Chen X; Yu A; Xia L; Zhang P
    BMC Cancer; 2018 Nov; 18(1):1147. PubMed ID: 30463533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The surgical management of women with ovarian cancer in the south west of England.
    Olaitan A; Weeks J; Mocroft A; Smith J; Howe K; Murdoch J
    Br J Cancer; 2001 Dec; 85(12):1824-30. PubMed ID: 11747321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
    Vergote IB; De Wever I; Decloedt J; Tjalma W; Van Gramberen M; van Dam P
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):31-6. PubMed ID: 10952124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival of patients with apparent early-stage (FIGO I-II) epithelial ovarian cancer: a population-based study.
    Petignat P; de Weck D; Goffin F; Vlastos G; Obrist R; Luthi JC
    Gynecol Obstet Invest; 2007; 63(3):132-6. PubMed ID: 17057398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
    Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
    Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
    Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.